Laddar populära aktier...
Orders -2%, sales +1%, EBITA -18% vs. ABGSCe Unspecified non-recurring items related to improvement ...
Redeye comments on the US CMS rate change for 2025.
Redeye provides an initial comment on the Q3 2024 report from Cheffelo, which came in below our esti...
Redeye updates on Gentoo Media after its pre-announced Q3-results which was close to our forecast wh...
Last year was a fairly weak one for Tallinna Sadam, but the tone has changed for 2024.
IRLAB’s Q324 results highlighted progress across its clinical pipeline.
AVTECH announced it signed Iberojet, a Charter airline with seven aircraft.
Redeye views today’s press release from Acarix as a positive development, confirming new reimburseme...
While the Q3’24 report did not contain any particular surprises in terms of financials, it did provi...
Redeye initiates coverage of MedCap, a serial acquirer of niche life science SMEs that has posted st...
Ahead of Relais Q3 report, we maintain our estimates intact.
Redeye comments on BioInvent's Q3 report, which presented new data for the subcutaneous version of B...
Exel’s Q3 figures disappointed due to the continued demand softness, however EBIT has plenty of pote...
Redeye comments on Tessin’s Q3 results, which were weaker than expected.
Redeye provides an update following CLS’s Q3 2024 report.
